Zonisamide

CAS 68291-97-4 11 current records 8 historicalSmall Molecule

Who holds supplier records for Zonisamide? 11 organisations hold a current record for Zonisamide: an active US FDA Type II Drug Master File. A further 8 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (9), Italy (1) and Japan (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Zonisamide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/zonisamide

Reading the evidence

  • 11 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    9 of the 11 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 9 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Zonisamide expires 18 Aug 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (11)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Zonisamide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Zonisamide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (8)

Organisations whose Type II DMFs for Zonisamide are no longer active. These show a past filing, not current supply.

Show all 8 historical records
  • Bachem SA, Succursale de Vionnaz
    Switzerland · Inactive DMF 22276 · filed Dec 2008
  • APOTEX PHARMACHEM INC
    Inactive DMF 18203 · filed Mar 2005
  • Teva Pharmaceutical Industries Ltd.
    Israel · Inactive DMF 18197 · filed Mar 2005
  • India · Inactive DMF 18103 · filed Feb 2005
  • MYLAN LABORATORIES LTD
    Inactive DMF 17975 · filed Jan 2005
  • Japan · Inactive DMF 17661 · filed Sept 2004
  • Italy · Inactive DMF 17254 · filed Mar 2004
  • PERRIGO API LTD
    Inactive DMF 17027 · filed Nov 2003

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (24 listed products contain Zonisamide). The latest listed patent expires 18 Aug 2038. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Zonisamide is a sulfonamide anticonvulsant medication primarily used to treat partial seizures in adults. It works by inhibiting sodium channels and reducing current through T-type calcium channels, which stabilizes neuronal activity.

Chemical identity

IUPAC name
1,2-benzoxazol-3-ylmethanesulfonamide
Canonical SMILES
C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
InChIKey
UBQNRHZMVUUOMG-UHFFFAOYSA-N
Synonyms
Zonegran API, ad-810, ci-912, excegran, n03ax15, pd-110843, zonegran, zonisade

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Anti-epileptic Agent
Mechanism of action
Carbonic Anhydrase Inhibitors; P-Glycoprotein Inhibitors
Physiologic effect
Decreased Central Nervous System Disorganized Electrical Activity
Chemical structure
Sulfonamides

Therapeutic areas

NeurologySeizures

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Zonisamide?

11 organisations hold an active US FDA Type II Drug Master File or a CEP for Zonisamide: ALIVUS LIFE SCIENCES LTD (India), COHANCE LIFESCIENCES LTD (India), Dipharma Francis Srl (Italy), EMNAR PHARMA PRIVATE LTD (India), Hetero Labs Limited (India), MAITHRI DRUGS PRIVATE LTD (India), Sumitomo Pharma Co., Ltd. (Japan) and Sun Pharmaceutical Industries Limited (India), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Zonisamide Drug Master Files are active?

ALIVUS LIFE SCIENCES LTD (DMF 31973, 17945), COHANCE LIFESCIENCES LTD (DMF 33256, 31298), Dipharma Francis Srl (DMF 17303), EMNAR PHARMA PRIVATE LTD (DMF 38524), Hetero Labs Limited (DMF 18488), MAITHRI DRUGS PRIVATE LTD (DMF 31009), Sumitomo Pharma Co., Ltd. (DMF 12198) and Sun Pharmaceutical Industries Limited (DMF 18191) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Zonisamide records mean?

8 organisations have only inactive Type II DMFs for Zonisamide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Zonisamide?

Yes. The latest patent listed for an approved US product containing Zonisamide expires 18 Aug 2038, across 24 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Zonisamide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Zonisamide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.